Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1.

Trial Profile

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2012

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Cancer; Neurofibromatoses; Tuberous sclerosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 24 Feb 2012 Actual patient number 52 added as reported by ClinicalTrials.gov.
    • 24 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jun 2010 Planned end date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top